Phase 2 Readout~quarter

Phase 2 Readout: silevertinib

Indication
GBM

Other upcoming events for BDTX

Patent ExpiryPatent/Exclusivity Expiry: FIBRICOR
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnos
Phase 3 ReadoutPhase 3 Topline: PH Weighted Chemical Exchange Saturation Transfer Based Surgical Resections of Glioblastoma
Patent ExpiryPatent/Exclusivity Expiry: IWILFIN
Patent ExpiryPatent/Exclusivity Expiry: SEGLENTIS

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Readout: silevertinib — BDTX Phase 2 Readout | BioSniper